Liquid biopsy is a collection and analysis of usually noninvasive liquid biological tissue for the diagnosis and monitoring of diseases. It is the direct clinical application of two developments in medical science, namely the sequencing of the human genome and the increasing sensitivity of detection techniques and assays. The global liquid biopsy market share is expected to grow at a CAGR of 28% during the forecast period, 2015-2022, according to Market Research Future.

Liquid biopsy uses the qualitative and quantitative differences amid various biomarkers such as circulating tumor cells (CTC), cell-free DNA, methylated ctAD, miRNA in a patient's blood, and cell-free RNA fragments (rRNA). Although some of these markers are seen even under other circumstances, such as trauma, there is a quantitative variance in form, degree of fragmentation, concentration, and composition.

Get Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/710

Factors such as cancer rates, investment in research and development, cooperation between public organizations and companies, rising health care costs, increasing elderly population, rising health care costs, and others are the most important driving factors of liquid biopsy market growth. However, not all cancers, such as brain cancer and prostate cancer, may remain dormant for many years. An additional fluid biopsy is not invasive, as can be observed when brain fluid is used as a sample.

Invaluable costs associated with liquid biopsy and differentiated awareness and availability between developing countries and the developed nations are some of the factors inhibiting the growth of the global liquid biopsy market.

Key Players

The global liquid biopsy market is supported by various market giants with advanced product portfolio and innovations. Some of these industry giants include RainDance Technologies, Inc., Trovagene, Inc., Biocept, Inc, Exosome Diagnostics, Circulogene Theranostics, SAGA Diagnostics AB, Admera Health, Guardant Health, Inc., Agena Bioscience Inc., KGaA, and Inivata Ltd.

Market Segmentation

The global liquid biopsy market is split based on biomarker types, applications, samples, and end-users.

Based on the types of biomarkers, the global market is segmented into circulating tumor DNA (CTDNA), circulating tumor cells (CTCS), extracellular vesicles (EVS), and others.
Based on the applications, the global market was bifurcated into reproductive health, cancer, and so on. The sample segment is divided into the global market is divided into urine samples, blood samples, forensic samples, and others.
Based on the end-user, the global market is classified into hospitals, academic and research centers, laboratories, and other end users. Advancements in diagnostic technologies, for example, cell capture technology, digital PCR, and multi-panel detection, are driving the commercial application segment of the global market.
Regional Outlook

North America held the largest market share, with 37.95% in 2016, and the Asia Pacific was the fastest-growing market. Liquid biopsy technology has been developed in the United States and several European countries, resulting in the supremacy of these two regions in their respective market shares.

The European market is expected to have an exceptional annual growth of 28.5%. Venture capital available to life science companies has doubled between 2001 and 2010. In Europe, the UK holds almost 20% of all investments, and almost 20% of UK venture capital is invested in the healthcare sector. The Asia Pacific region is the fastest-growing market and is expected to reach a CAGR of 29.7% over the forecast period.

Get Access Full Report @ https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710

The Middle East and Africa should have limited markets but steady growth. In 2012, around 14 million new cases and 8.2 million cancer-related deaths were reported globally, and this number is anticipated to reach 22 million over the next two decades.

Industry Updates

RareCyte introduced a novel RarePlex Staining Kit, which will allow customers to assess prostate cancer-specific countenance of ARv7 on CTC (circulating tumor cells) in their inbuilt lab. ARv7 is the outcome of a joint variant of Androgen Receptor (AR), which is a prostate cancer biomarker used for diagnostics, and ARv7 is linked with resistance to second-generation procedures.